The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334.

Inclusion criteria

：

• Subjects with the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol;
• Male or female subjects ≥ 18 years old;
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;
• Anticipated life expectancy of ≥ 12 weeks;
• At least 1 evaluable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1with Phase Ia ;At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 with Phase Ib+II；

Exclusion criteria

：

• Participate in any other interventional clinical research except observational (non-interventional) study or in the follow-up phase of the interventional study;
• Received live vaccines within 4 weeks prior to first dose of the study drug or plan on receiving any live vaccine during the study;
• History of immunodeficiency disease, including congenital or acquired immunodeficiency diseases;
• Severe allergic or hypersensitive to other EGFR or B7H3 antibodies or any ingredients of IBI334;
• Plan to receive other antitumor therapy during the study excluding palliative radiotherapy for the purpose of symptom (like pain) relief, which must not affect tumor assessment throughout the study;